Last quarter (Q ), Amryt Pharma's total revenue was $61.13M, an increase of 8.15% from the same quarter last year. In Q, Amryt Pharma's net income was $-20.80M. See Amryt Pharma’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 21	Dec 20	Dec 19	Dec 18	Dec 17
Total Revenue	$ 243.62M	$ 222.54M	$ 182.61M	$ 58.12M	$ 17.09M	$ 15.33M
Cost of Revenue	$ 127.03M	$ 106.12M	$ 119.03M	$ 38.73M	$ 6.27M	$ 6.45M
Gross Profit	$ 116.59M	$ 116.42M	$ 63.58M	$ 19.39M	$ 10.83M	$ 8.88M
Operating Expense	$ 161.67M	$ 129.72M	$ 109.02M	$ 52.17M	$ 28.87M	$ 25.93M
Operating Income	$ -45.08M	$ -13.30M	$ -45.44M	$ -32.77M	$ -18.04M	$ -17.04M
Net Non Operating Interest Income Expense	$ -27.84M	$ 5.28M	$ -22.27M	$ -10.02M	$ -1.62M	$ -1.01M
Other Income Expense	$ 71.56M	$ -4.42M	$ -38.15M	$ -22.21M	$ -10.79M	-
Pretax Income	$ -1.36M	$ -2.14M	$ -105.86M	$ -63.49M	$ -30.44M	$ -31.36M
Tax Provision	$ -572.00K	$ -7.56M	$ -1.33M	$ -495.00K	$ 43.00K	$ 0.00
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -790.00K	$ 5.42M	$ -104.53M	$ -63.00M	$ -30.49M	$ -31.36M
Basic EPS	-	-	-	-	-	-
Diluted EPS	-	-	-	-	-	-
Basic Average Shares	-	-	-	-	-	-
Diluted Average Shares	-	-	-	-	-	-
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	$ 623.00K	$ 170.00K	$ 300.00K	$ 337.12K
Total Expenses	$ 288.70M	$ 235.84M	$ 228.05M	$ 90.90M	$ 35.13M	$ 32.37M
Net Income From Continuing And Discontinued Operation	$ -790.00K	$ 5.42M	$ -104.53M	$ -63.00M	$ -30.49M	$ -31.36M
Normalized Income	$ -60.91M	-	$ -66.86M	$ -38.74M	$ -13.19M	$ -18.03M
Interest Expense	$ 27.54M	-	$ 22.34M	$ 9.99M	$ 1.60M	$ 1.01M
EBIT	$ 26.18M	$ -7.42M	$ -83.52M	$ -53.50M	$ -28.84M	$ -30.34M
EBITDA	$ 72.85M	$ 47.74M	$ -39.06M	$ -41.22M	$ -28.47M	$ -30.03M

Currency in USD

Amryt Pharma Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing